SCHEMBL4214728

SCHEMBL4214728

O=C(O)c1ccc(-c2ccccc2)cc1Nc1ccccc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 11/20 0.54
GRIK1 P39086 1/20 0.51
HNF4A P41235 2/20 0.50
ACMSD Q8TDX5 2/20 0.50
MCL1 Q07820 2/20 0.50
FABP3 P05413 1/20 0.50
FABP4 P15090 1/20 0.50
FABP5 Q01469 1/20 0.50
DHFR P00374 1/20 0.50
KDM4E B2RXH2 2/20 0.49
APAF1 O14727 1/20 0.49
RECQL P46063 1/20 0.49
CASP6 P55212 1/20 0.49
CACNA1B Q00975 1/20 0.49
APBA1 Q02410 1/20 0.49
CASP8 Q14790 1/20 0.49
AKR1B10 O60218 1/20 0.49
AKR1B1 P15121 1/20 0.49
AKR1C4 P17516 1/20 0.49
AKR1C3 P42330 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4213528 0.87 MAPT (0.52) ACLYHNF4AACMSDFABP3FABP4
SCHEMBL14576318 0.84 GRIK1 (0.54) GRIK1FABP3FABP4FABP5KDM4E
SCHEMBL4218109 0.83 ACMSD (0.60) ACLYGRIK1HNF4AACMSDMCL1
SCHEMBL4217337 0.83 FABP3 (0.73) ACLYHNF4AACMSDMCL1FABP3
SCHEMBL4256425 0.82 FABP4 (0.65) GRIK1FABP3FABP4FABP5DHFR
SCHEMBL4223433 0.82 FABP4 (0.58) ACLYHNF4AACMSDMCL1FABP3
SCHEMBL4216661 0.82 FTO (0.58) ACLYGRIK1FABP3FABP4FABP5
SCHEMBL4217591 0.82 ACLY (0.44) ACLYMCL1KDM4EAPAF1RECQL
SCHEMBL4222990 0.81 ACLY (0.59) ACLYGRIK1HNF4AACMSDMCL1
SCHEMBL6800630 0.81 CTSV (0.53) GRIK1ACMSDFABP3FABP4FABP5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 ACLY 430/4885GRIK1 469/4885HNF4A 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.